Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267984 | 0.69 | — | — | |
| SCHEMBL6543758 | 0.69 | ACHE (0.36) | LMNAMAPTPOLBPKMKDM4E | |
| SCHEMBL4265728 | 0.68 | LMNA (0.44) | LMNAMAPTPOLBPKMKDM4E | |
| SCHEMBL12470613 | 0.67 | HSP90AA1 (0.40) | LMNAMAPTPOLBPKMKDM4E | |
| SCHEMBL27419554 | 0.67 | LMNA (0.36) | LMNAMAPTPOLBPKMKDM4E | |
| SCHEMBL1828481 | 0.65 | SMN1; SMN2 (0.41) | LMNAMAPTPOLBPKMKDM4E | |
| SCHEMBL4916006 | 0.65 | MAPK1 (0.42) | MAPTPOLBKDM4ETSHRALDH1A1 | |
| SCHEMBL30575119 | 0.65 | HSP90AA1 (0.39) | LMNAMAPTPOLBPKMKDM4E | |
| SCHEMBL29080505 | 0.65 | HSP90AA1 (0.39) | LMNAMAPTPOLBPKMKDM4E | |
| SCHEMBL27813844 | 0.65 | LMNA (0.39) | LMNAKDM4ECYP3A4TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | claimed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | claimed |
| US-4323569-A | β-Lactam anti-bacterial, compositions containing them and a process for their preparation | BEECHAM GROUP LIMITED (GB) | 1982-04-06 | — | — | US | claimed |
| EP-0008514-B1 | BETA-LACTAM ANTI-BACTERIALS, COMPOSITIONS CONTAINING THEM AND A PROCESS FOR THEIR PREPARATION | BEECHAM GROUP PLC (GB) | 1982-01-20 | — | — | EP | claimed |
| EP-0008514-A1 | Beta-lactam anti-bacterials, compositions containing them and a process for their preparation | BEECHAM GROUP PLC (GB) | 1980-03-05 | — | — | EP | claimed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-2672967-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9624213-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-4323569-A | β-Lactam anti-bacterial, compositions containing them and a process for their preparation | BEECHAM GROUP LIMITED (GB) | 1982-04-06 | — | — | US | disclosed |
| EP-0008514-B1 | BETA-LACTAM ANTI-BACTERIALS, COMPOSITIONS CONTAINING THEM AND A PROCESS FOR THEIR PREPARATION | BEECHAM GROUP PLC (GB) | 1982-01-20 | — | — | EP | disclosed |
| EP-0008514-A1 | Beta-lactam anti-bacterials, compositions containing them and a process for their preparation | BEECHAM GROUP PLC (GB) | 1980-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | LMNA 2215/4885MAPT 2286/4885POLB 1542/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | LMNA 2215/4885MAPT 2286/4885POLB 1542/4885 |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | LMNA 2215/4885MAPT 2286/4885POLB 1542/4885 |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | LMNA 2215/4885MAPT 2286/4885POLB 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.